A Phase 3 interventional study of V116 and PCV20 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 112 sites in 11 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one has the largest enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 3rd registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2022.
This study's enrollment of 2,663 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one has the largest enrollment, is one of 5 that started in 2022, is one of 31 in phase 3, and was the 37th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine ([Prevnar 20™ / APEXXNAR™]) in pneumococcal vaccine-naïve adults. It is hypothesized that V116 is noninferior to PCV20 for the common serotypes and superior to PCV20 for the unique serotypes as assessed by serotype specific opsonophagocytic activity (OPA) 30 days postvaccination. It is also hypothesized that V116 in participants 18 to 49 years of age immunobridges to V116 in participants 50 to 64 years of age as assessed by serotype specific OPA geometric mean titers (GMTs) 30 days postvaccination for all 21 serotypes in V116. Participants ≥50 years of age will be enrolled in Cohort 1, and participants 18 to 49 years of age will be enrolled in Cohort 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of V116 on Day 1.
Biological: V116
Pneumococcal vaccine-naïve adult participants (≥50 years of age) receive a single dose of PCV20 on Day 1.
Biological: PCV20
Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of V116 on Day 1.
Biological: V116
Pneumococcal vaccine-naïve adult participants (18 to 49 years of age) receive a single dose of PCV20 on Day 1.
Biological: PCV20
0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
Also known as: Pneumococcal 21-valent Conjugate Vaccine
0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
Also known as: Prevnar 20™, APEXXNAR™
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C)
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Vaccine-related Serious AE (SAE)
A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event, which is determined by the investigator to be related to the vaccine.
Time frame: Up to 194 days post-vaccination
Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20
The serotype specific OPA GMTs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using the multiplex opsonophagocytic assay (MOPA). GMT values were estimated from a constrained longitudinal data analysis; (cLDA) model. Per protocol, within group, confidence intervals (CIs) or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Day 30 post-vaccination
Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses in Cohort 1 Only for the 11 Unique Pneumococcal Serotypes Contained in V116
The percentage of participants with ≥4-fold rise from baseline in serotype specific OPAs for the 11 unique pneumococcal serotypes contained in V116. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Serotype Specific OPA GMTs in Participants 18-49 Years and Participants 50-64 Years for the Pneumococcal Serotypes Contained in V116
The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA. GMT values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.
Time frame: Day 30 post-vaccination
Percentage of Participants From Cohort 1 V116 With ≥4-fold Change in OPA Responses for Cross Reactive Pneumococcal Serotypes
The percentage of participants with ≥4-fold rise from baseline was determined for Cohort 1 V116 serotypes 6C and 15B, two serotypes which cross react with PCV20. Point estimate and 95% CI are based on the Clopper-Pearson method. A conclusion of acceptability is based on the lower bound of the 95% CI of the percentages of participants with a ≥4-fold rise from baseline being \> 50 percentage points (one-sided p-value \< 0.025). Per protocol, participants treated with PCV20, and V116 Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Serotype Specific OPA GMTs for Cross Reactive Pneumococcal Serotypes in Adults 50 to 64 Years of Age From Cohort 1 and Adults 18 to 49 Years of Age From Cohort 2
The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA for serotypes 6C and 15B which cross react with PCV20. GMT values were estimated from a LDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.
Time frame: Day 30 post-vaccination
Serotype Specific Immunoglobulin (IgG) Geometric Mean Concentrations (GMCs) in Cohort 1 Only, for the Pneumococcal Serotypes Contained in V116 and PCV20
The serotype specific IgG GMCs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using pneumococcal electrochemiluminescence (PnECL). GMC values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Day 30 post-vaccination
Geometric Mean Fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
The geometric mean fold rise (GMFR) from baseline in serotype specific OPA GMTs for cohort 1 was determined using MOPA. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Geometric Mean Fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
The GMFR from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Percentage of Participants With ≥4-fold Change From Baseline in IgG Antibody GMCs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
Percentage of participants with ≥4-fold rise from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Percentage of Participants With ≥4-fold Change From Baseline in OPA GMTs in Cohort 1 for the Pneumococcal Serotypes Contained in V116 and PCV20
Percentage of participants with ≥4-fold rise from baseline in OPA GMTs in Cohort 1 was determined using MOPA. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
Time frame: Baseline and Day 30 post-vaccination
Pneumococcal vaccine-naïve adults ≥18 years of age were enrolled in this study. Participants with underlying chronic conditions were eligible if the conditions were assessed to be stable per the investigator's judgment.
| Milestone | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Started | 1181 | 1181 | 201 | 100 |
| Vaccinated | 1179 | 1177 | 200 | 100 |
| Safety all cause mortality (acm) population | 1179 | 1179 | 201 | 100 |
| All participants as treated (apat) | 1177 | 1175 | 200 | 100 |
| Safety adverse event (ae) population | 1177 | 1175 | 200 | 100 |
| Completed | 1160 | 1152 | 195 | 96 |
| Not completed | 21 | 29 | 6 | 4 |
| Withdrew: Death | 4 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 15 | 5 | 3 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 |
| Withdrew: Randomized by mistake without study treatment | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 8 | 1 | 1 |
| Withdrew: Randomized to pcv20 first, discontinued; then randomized to v116 second | 2 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Injection site erythema | 5.4 | 6.3 | 15.5 | 13.0 |
| Injection site pain | 39.4 | 51.7 | 71.5 | 74.0 |
| Injection site swelling | 6.0 | 8.3 | 14.0 | 14.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C)
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Fatigue | 20.1 | 19.6 | 40.5 | 34.0 |
| Headache | 11.5 | 12.9 | 29.5 | 24.0 |
| Myalgia | 5.9 | 6.7 | 16.5 | 14.0 |
| Pyrexia | 1.3 | 1.3 | 3.5 | 1.0 |
A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event, which is determined by the investigator to be related to the vaccine.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Percentage of Participants With Vaccine-related Serious AE (SAE) | 0.0 | 0.0 | 0.0 | 0.0 |
The serotype specific OPA GMTs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using the multiplex opsonophagocytic assay (MOPA). GMT values were estimated from a constrained longitudinal data analysis; (cLDA) model. Per protocol, within group, confidence intervals (CIs) or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| Titer | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 274.0 (NA to NA) | 176.7 (NA to NA) | — | — |
| Serotype 6A | 2302.0 (NA to NA) | 2972.5 (NA to NA) | — | — |
| Serotype 7F | 3637.4 (NA to NA) | 3429.9 (NA to NA) | — | — |
| Serotype 8 | 2501.3 (NA to NA) | 1811.1 (NA to NA) | — | — |
| Serotype 10A | 3893.4 (NA to NA) | 4678.0 (NA to NA) | — | — |
| Serotype 11A | 3232.6 (NA to NA) | 2092.8 (NA to NA) | — | — |
| Serotype 12F | 2641.2 (NA to NA) | 2499.6 (NA to NA) | — | — |
| Serotype 19A | 2136.1 (NA to NA) | 2817.8 (NA to NA) | — | — |
| Serotype 22F | 3874.5 (NA to NA) | 4770.1 (NA to NA) | — | — |
| Serotype 33F | 13558.9 (NA to NA) | 11742.1 (NA to NA) | — | — |
| Serotype 9N | 7470.7 (NA to NA) | 1640.4 (NA to NA) | — | — |
| Serotype15A | 5237.2 (NA to NA) | 1589.0 (NA to NA) | — | — |
| Serotype 15C | 4216.2 (NA to NA) | 2072.3 (NA to NA) | — | — |
| Serotype 16F | 4868.2 (NA to NA) | 846.3 (NA to NA) | — | — |
| Serotype 17F | 7764.9 (NA to NA) | 460.4 (NA to NA) | — | — |
| Serotype 20A | 6099.2 (NA to NA) | 631.1 (NA to NA) | — | — |
| Serotype 23A | 3737.2 (NA to NA) | 461.5 (NA to NA) | — | — |
| Serotype 23B | 1082.5 (NA to NA) | 107.3 (NA to NA) | — | — |
| Serotype 24F | 2728.6 (NA to NA) | 70.5 (NA to NA) | — | — |
| Serotype 31 | 3132.5 (NA to NA) | 144.4 (NA to NA) | — | — |
| Serotype 35B | 8527.8 (NA to NA) | 1383.0 (NA to NA) | — | — |
The percentage of participants with ≥4-fold rise from baseline in serotype specific OPAs for the 11 unique pneumococcal serotypes contained in V116. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 9N | 64.7 (NA to NA) | 19.9 (NA to NA) | — | — |
| Serotype 15A | 66.7 (NA to NA) | 35.8 (NA to NA) | — | — |
| Serotype 15C | 83.4 (NA to NA) | 74.2 (NA to NA) | — | — |
| Serotype 16F | 71.9 (NA to NA) | 20.8 (NA to NA) | — | — |
| Serotype 17F | 75.8 (NA to NA) | 9.5 (NA to NA) | — | — |
| Serotype 20A | 67.3 (NA to NA) | 9.6 (NA to NA) | — | — |
| Serotype 23A | 78.9 (NA to NA) | 36.8 (NA to NA) | — | — |
| Serotype 23B | 85.5 (NA to NA) | 49.6 (NA to NA) | — | — |
| Serotype 24F | 80.5 (NA to NA) | 6.3 (NA to NA) | — | — |
| Serotype 31 | 76.5 (NA to NA) | 17.9 (NA to NA) | — | — |
| Serotype 35B | 60.0 (NA to NA) | 6.8 (NA to NA) | — | — |
The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA. GMT values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.
| Titer | V116 18 to 49 Years Old | V116 50 to 64 Years Old | Cohort 1 PCV20 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 308.6 (NA to NA) | 282.7 (NA to NA) | — | — |
| Serotype 6A | 5289.6 (NA to NA) | 2572.9 (NA to NA) | — | — |
| Serotype 7F | 6447.2 (NA to NA) | 4278.8 (NA to NA) | — | — |
| Serotype 8 | 4516.0 (NA to NA) | 3004.7 (NA to NA) | — | — |
| Serotype 9N | 17283.2 (NA to NA) | 8791.4 (NA to NA) | — | — |
| Serotype 10A | 6808.1 (NA to NA) | 4382.6 (NA to NA) | — | — |
| Serotype 11A | 5871.6 (NA to NA) | 3785.8 (NA to NA) | — | — |
| Serotype 12F | 6150.4 (NA to NA) | 3561.2 (NA to NA) | — | — |
| Serotype 15A | 11319.2 (NA to NA) | 5901.2 (NA to NA) | — | — |
| Serotype 15C | 10194.0 (NA to NA) | 5708.0 (NA to NA) | — | — |
| Serotype 16F | 8877.0 (NA to NA) | 5720.0 (NA to NA) | — | — |
| Serotype17F | 16070.6 (NA to NA) | 10068.0 (NA to NA) | — | — |
| Serotype 19A | 2773.2 (NA to NA) | 2374.6 (NA to NA) | — | — |
| Serotype 20A | 13150.0 (NA to NA) | 7562.7 (NA to NA) | — | — |
| Serotype 22F | 9299.6 (NA to NA) | 4683.6 (NA to NA) | — | — |
| Serotype 23A | 8848.7 (NA to NA) | 4739.5 (NA to NA) | — | — |
| Serotype 23B | 2140.1 (NA to NA) | 1420.9 (NA to NA) | — | — |
| Serotype 24F | 4137.6 (NA to NA) | 3047.2 (NA to NA) | — | — |
| Serotype 31 | 8005.6 (NA to NA) | 3820.7 (NA to NA) | — | — |
| Serotype 33F | 34805.5 (NA to NA) | 17607.4 (NA to NA) | — | — |
| Serotype 35B | 13933.4 (NA to NA) | 9053.9 (NA to NA) | — | — |
The percentage of participants with ≥4-fold rise from baseline was determined for Cohort 1 V116 serotypes 6C and 15B, two serotypes which cross react with PCV20. Point estimate and 95% CI are based on the Clopper-Pearson method. A conclusion of acceptability is based on the lower bound of the 95% CI of the percentages of participants with a ≥4-fold rise from baseline being \> 50 percentage points (one-sided p-value \< 0.025). Per protocol, participants treated with PCV20, and V116 Cohort 2 were not analyzed in this outcome measure.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 6C | 49.3 (46.0 to 52.6) | — | — | — |
| Serotype 15B | 64.7 (61.4 to 67.8) | — | — | — |
The serotype specific OPA GMTs for the pneumococcal serotypes in participants 18-49 years and participants 50-64 years treated with V116 only were determined using the MOPA for serotypes 6C and 15B which cross react with PCV20. GMT values were estimated from a LDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. Per protocol, participants treated with PCV20 were not analyzed in this outcome measure.
| Titer | V116 18 to 49 Years Old | V116 50 to 64 Years Old | Cohort 1 PCV20 | Cohort 2 PCV20 |
|---|---|---|---|---|
| 6C | 2577.2 (NA to NA) | 1254.7 (NA to NA) | — | — |
| 15B | 10976.7 (NA to NA) | 5438.9 (NA to NA) | — | — |
The serotype specific IgG GMCs for the pneumococcal serotypes in cohort 1 of V116 and PCV20 only were determined using pneumococcal electrochemiluminescence (PnECL). GMC values were estimated from a cLDA model. Per protocol, within group CIs or any other measures of dispersion were not planned or determined. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| μg/mL | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 0.78 (NA to NA) | 0.53 (NA to NA) | — | — |
| Serotype 6A | 4.30 (NA to NA) | 5.45 (NA to NA) | — | — |
| Serotype 7F | 6.97 (NA to NA) | 6.57 (NA to NA) | — | — |
| Serotype 8 | 10.02 (NA to NA) | 7.00 (NA to NA) | — | — |
| Serotype 10A | 11.98 (NA to NA) | 14.66 (NA to NA) | — | — |
| Serotype 11A | 7.20 (NA to NA) | 5.87 (NA to NA) | — | — |
| Serotype 12F | 1.73 (NA to NA) | 1.57 (NA to NA) | — | — |
| Serotype 19A | 8.39 (NA to NA) | 12.02 (NA to NA) | — | — |
| Serotype 22F | 4.39 (NA to NA) | 5.48 (NA to NA) | — | — |
| Serotype 33F | 13.81 (NA to NA) | 13.02 (NA to NA) | — | — |
| Serotype 9N | 7.72 (NA to NA) | 1.43 (NA to NA) | — | — |
| Serotype15A | 13.88 (NA to NA) | 2.04 (NA to NA) | — | — |
| Serotype 15C | 12.39 (NA to NA) | 5.04 (NA to NA) | — | — |
| Serotype 16F | 2.86 (NA to NA) | 0.33 (NA to NA) | — | — |
| Serotype 17F | 14.16 (NA to NA) | 0.84 (NA to NA) | — | — |
| Serotype 20A | 19.03 (NA to NA) | 1.47 (NA to NA) | — | — |
| Serotype 23A | 3.78 (NA to NA) | 0.59 (NA to NA) | — | — |
| Serotype 23B | 5.13 (NA to NA) | 1.58 (NA to NA) | — | — |
| Serotype 24F | 6.87 (NA to NA) | 0.33 (NA to NA) | — | — |
| Serotype 31 | 3.07 (NA to NA) | 0.27 (NA to NA) | — | — |
| Serotype 35B | 19.98 (NA to NA) | 1.41 (NA to NA) | — | — |
The geometric mean fold rise (GMFR) from baseline in serotype specific OPA GMTs for cohort 1 was determined using MOPA. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| GMFR | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 8.4 (7.7 to 9.1) | 5.4 (5.0 to 5.8) | — | — |
| Serotype 6A | 18.1 (16.2 to 20.2) | 22.6 (20.1 to 25.5) | — | — |
| Serotype 7F | 16.5 (14.4 to 18.8) | 14.7 (12.9 to 16.8) | — | — |
| Serotype 8 | 22.0 (19.3 to 25.0) | 14.2 (12.5 to 16.2) | — | — |
| Serotype 10A | 16.7 (14.8 to 18.9) | 20.8 (18.3 to 23.8) | — | — |
| Serotype11A | 17.4 (15.1 to 20.0) | 11.6 (10.1 to 13.3) | — | — |
| Serotype 12F | 77.4 (68.5 to 87.4) | 73.5 (64.8 to 83.4) | — | — |
| Serotype 19A | 8.6 (7.7 to 9.5) | 11.0 (9.9 to 12.2) | — | — |
| Serotype 22F | 19.1 (16.6 to 22.1) | 25.5 (21.9 to 29.8) | — | — |
| Serotype 33F | 9.9 (8.9 to 11.1) | 8.5 (7.6 to 9.5) | — | — |
| Serotype 9N | 8.9 (8.0 to 9.9) | 2.0 (1.9 to 2.2) | — | — |
| Serotype 15A | 9.4 (8.2 to 10.8) | 3.1 (2.7 to 3.5) | — | — |
| Serotype 15C | 38.0 (33.3 to 43.3) | 20.3 (17.8 to 23.1) | — | — |
| Serotype 16F | 9.5 (8.7 to 10.4) | 1.9 (1.7 to 2.0) | — | — |
| Serotype 17F | 17.3 (15.3 to 19.7) | 1.2 (1.1 to 1.3) | — | — |
| Serotype 20A | 10.3 (9.2 to 11.4) | 1.2 (1.1 to 1.2) | — | — |
| Serotype 23A | 21.8 (19.0 to 25.0) | 3.1 (2.7 to 3.6) | — | — |
| Serotype 23B | 51.4 (45.3 to 58.2) | 6.1 (5.4 to 6.9) | — | — |
| Serotype 24F | 29.0 (25.6 to 32.8) | 1.1 (1.0 to 1.1) | — | — |
| Serotype 31 | 28.7 (24.9 to 33.1) | 1.5 (1.4 to 1.7) | — | — |
| Serotype 35B | 7.2 (6.5 to 7.9) | 1.2 (1.1 to 1.2) | — | — |
The GMFR from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| GMFR | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 5.1 (4.8 to 5.4) | 3.5 (3.3 to 3.7) | — | — |
| Serotype 6A | 12.2 (11.1 to 13.5) | 15.1 (13.8 to 16.6) | — | — |
| Serotype 7F | 12.5 (11.5 to 13.7) | 12.2 (11.2 to 13.4) | — | — |
| Serotype 8 | 12.6 (11.5 to 13.8) | 8.8 (8.0 to 9.6) | — | — |
| Serotype 10A | 15.4 (14.1 to 16.9) | 19.2 (17.4 to 21.1) | — | — |
| Serotype11A | 8.7 (8.1 to 9.5) | 7.1 (6.5 to 7.7) | — | — |
| Serotype 12F | 13.1 (11.8 to 14.4) | 12.1 (11.0 to 13.5) | — | — |
| Serotype 19A | 5.4 (5.0 to 5.8) | 7.7 (7.1 to 8.4) | — | — |
| Serotype 22F | 12.7 (11.6 to 13.9) | 16.3 (14.8 to 17.9) | — | — |
| Serotype 33F | 9.6 (8.8 to 10.5) | 9.1 (8.3 to 9.9) | — | — |
| Serotype 9N | 15.0 (13.6 to 16.5) | 2.7 (2.5 to 2.9) | — | — |
| Serotype 15A | 22.3 (20.3 to 24.4) | 3.4 (3.1 to 3.7) | — | — |
| Serotype 15C | 19.8 (17.9 to 21.8) | 8.2 (7.4 to 9.0) | — | — |
| Serotype 16F | 13.3 (12.3 to 14.4) | 1.6 (1.5 to 1.7) | — | — |
| Serotype 17F | 19.8 (18.0 to 21.7) | 1.2 (1.1 to 1.3) | — | — |
| Serotype 20A | 11.7 (10.8 to 12.8) | 0.9 (0.9 to 1.0) | — | — |
| Serotype 23A | 17.8 (16.3 to 19.5) | 2.9 (2.6 to 3.1) | — | — |
| Serotype 23B | 12.1 (11.1 to 13.3) | 3.8 (3.5 to 4.1) | — | — |
| Serotype 24F | 21.2 (19.3 to 23.4) | 1.1 (1.0 to 1.1) | — | — |
| Serotype 31 | 13.0 (12.0 to 14.0) | 1.2 (1.2 to 1.3) | — | — |
| Serotype 35B | 14.7 (13.6 to 16.0) | 1.0 (1.0 to 1.1) | — | — |
Percentage of participants with ≥4-fold rise from baseline in serotype specific IgG antibody GMCs for cohort 1 was determined using PnECL. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 56.5 (53.5 to 59.4) | 41.0 (38.0 to 44.0) | — | — |
| Serotype 6A | 73.1 (70.4 to 75.7) | 79.7 (77.2 to 82.1) | — | — |
| Serotype 7F | 76.4 (73.8 to 78.9) | 75.8 (73.2 to 78.4) | — | — |
| Serotype 8 | 75.8 (73.1 to 78.3) | 67.8 (64.9 to 70.6) | — | — |
| Serotype 10A | 80.3 (77.8 to 82.6) | 82.0 (79.5 to 84.2) | — | — |
| Serotype11A | 71.1 (68.4 to 73.8) | 62.7 (59.8 to 65.6) | — | — |
| Serotype 12F | 74.2 (71.5 to 76.7) | 71.4 (68.6 to 74.1) | — | — |
| Serotype 19A | 55.6 (52.6 to 58.5) | 65.0 (62.0 to 67.8) | — | — |
| Serotype 22F | 76.8 (74.2 to 79.3) | 78.5 (76.0 to 81.0) | — | — |
| Serotype 33F | 71.6 (68.8 to 74.2) | 66.7 (63.8 to 69.6) | — | — |
| Serotype 9N | 77.9 (75.3 to 80.3) | 29.4 (26.7 to 32.2) | — | — |
| Serotype 15A | 85.7 (83.5 to 87.8) | 37.7 (34.8 to 40.7) | — | — |
| Serotype 15C | 81.4 (78.9 to 83.6) | 63.2 (60.2 to 66.1) | — | — |
| Serotype 16F | 81.4 (78.9 to 83.6) | 11.8 (10.0 to 13.9) | — | — |
| Serotype 17F | 84.5 (82.2 to 86.6) | 4.3 (3.1 to 5.7) | — | — |
| Serotype 20A | 74.7 (72.1 to 77.3) | 1.3 (0.7 to 2.2) | — | — |
| Serotype 23A | 85.5 (83.3 to 87.6) | 29.4 (26.7 to 32.2) | — | — |
| Serotype 23B | 76.1 (73.4 to 78.6) | 42.2 (39.3 to 45.2) | — | — |
| Serotype 24F | 84.0 (81.7 to 86.1) | 2.3 (1.5 to 3.4) | — | — |
| Serotype 31 | 81.1 (78.6 to 83.4) | 3.9 (2.8 to 5.2) | — | — |
| Serotype 35B | 83.1 (80.8 to 85.3) | 3.3 (2.3 to 4.5) | — | — |
Percentage of participants with ≥4-fold rise from baseline in OPA GMTs in Cohort 1 was determined using MOPA. The within-group 95% CIs were based on the exact binomial method proposed by Clopper and Pearson. The 10 common pneumococcal serotypes in both V116 and PCV20 were as follows: 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. The 11 unique pneumococcal serotypes in V116 were as follows: 9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B. Per protocol, Cohort 2 were not analyzed in this outcome measure.
| Percentage of participants | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 |
|---|---|---|---|---|
| Serotype 3 | 71.3 (68.4 to 74.2) | 59.1 (55.9 to 62.3) | — | — |
| Serotype 6A | 76.8 (74.0 to 79.5) | 79.9 (77.2 to 82.4) | — | — |
| Serotype 7F | 71.0 (68.1 to 73.9) | 65.9 (62.8 to 68.9) | — | — |
| Serotype 8 | 75.8 (73.0 to 78.4) | 67.4 (64.3 to 70.3) | — | — |
| Serotype 10A | 71.9 (69.0 to 74.6) | 74.1 (71.3 to 76.9) | — | — |
| Serotype11A | 70.0 (66.9 to 73.0) | 61.5 (58.2 to 64.7) | — | — |
| Serotype 12F | 89.0 (87.0 to 90.9) | 87.1 (84.9 to 89.1) | — | — |
| Serotype 19A | 64.4 (61.3 to 67.3) | 70.2 (67.2 to 73.0) | — | — |
| Serotype 22F | 70.5 (67.5 to 73.4) | 74.4 (71.5 to 77.2) | — | — |
| Serotype 33F | 67.7 (64.6 to 70.7) | 61.5 (58.3 to 64.6) | — | — |
| Serotype 9N | 64.7 (61.5 to 67.8) | 19.9 (17.5 to 22.6) | — | — |
| Serotype 15A | 66.7 (63.0 to 70.2) | 35.8 (32.3 to 39.5) | — | — |
| Serotype 15C | 83.4 (80.9 to 85.7) | 74.2 (71.2 to 76.9) | — | — |
| Serotype 16F | 71.9 (68.8 to 74.8) | 20.8 (18.3 to 23.5) | — | — |
| Serotype 17F | 75.8 (72.7 to 78.6) | 9.5 (7.7 to 11.5) | — | — |
| Serotype 20A | 67.3 (64.3 to 70.2) | 9.6 (7.8 to 11.6) | — | — |
| Serotype 23A | 78.9 (75.8 to 81.7) | 36.8 (33.3 to 40.4) | — | — |
| Serotype 23B | 85.5 (83.2 to 87.6) | 49.6 (46.4 to 52.7) | — | — |
| Serotype 24F | 80.5 (77.8 to 83.0) | 6.3 (4.8 to 8.1) | — | — |
| Serotype 31 | 76.5 (73.6 to 79.3) | 17.9 (15.5 to 20.5) | — | — |
| Serotype 35B | 60.0 (56.7 to 63.2) | 6.8 (5.3 to 8.5) | — | — |
Collected over All-cause mortality (ACM): Randomization up to 194 days post-vaccination. Serous adverse events (SAEs): Treatment (Day 1) up to 194 days post-vaccination. Non-serious AEs (NSAEs): Treatment (Day 1) up to 30 days post-vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: V116 | 4/1,179 (0.3%) | 19/1,177 (1.6%) | 615/1,177 (52.3%) |
| Cohort 1: PCV20 | 2/1,179 (0.2%) | 24/1,175 (2%) | 722/1,175 (61.4%) |
| Cohort 2: V116 | 0/201 (0%) | 1/200 (0.5%) | 161/200 (80.5%) |
| Cohort 2: PCV20 | 0/100 (0%) | 3/100 (3%) | 78/100 (78%) |
| Unplanned Participants | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Cohort 1: V116 | Cohort 1: PCV20 | Cohort 2: V116 | Cohort 2: PCV20 | Unplanned Participants |
|---|---|---|---|---|---|
| Jejunal perforationGastrointestinal disorders | 0/1177 | 0/1175 | 0/200 | 1/100 | 0/2 |
| CellulitisInfections and infestations | 0/1177 | 0/1175 | 0/200 | 1/100 | 0/2 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/1177 | 0/1175 | 0/200 | 1/100 | 0/2 |
| Tooth abscessInfections and infestations | 0/1177 | 0/1175 | 1/200 | 0/100 | 0/2 |
| Myocardial infarctionCardiac disorders | 1/1177 | 4/1175 | 0/200 | 0/100 | 0/2 |
| SepsisInfections and infestations | 2/1177 | 0/1175 | 0/200 | 0/100 | 0/2 |
| Cerebrovascular accidentNervous system disorders | 2/1177 | 0/1175 | 0/200 | 0/100 | 0/2 |
| Cardiac arrestCardiac disorders | 1/1177 | 1/1175 | 0/200 | 0/100 | 0/2 |
| Coronary artery embolismCardiac disorders | 0/1177 | 1/1175 | 0/200 | 0/100 | 0/2 |
| VertigoEar and labyrinth disorders | 0/1177 | 1/1175 | 0/200 | 0/100 | 0/2 |
| Event | Cohort 1: V116 | Cohort 1: PCV20 | Cohort 2: V116 | Cohort 2: PCV20 | Unplanned Participants |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 471/1177 | 608/1175 | 143/200 | 74/100 | 0/2 |
| FatigueGeneral disorders | 240/1177 | 235/1175 | 81/200 | 34/100 | 0/2 |
| HeadacheNervous system disorders | 162/1177 | 174/1175 | 59/200 | 26/100 | 0/2 |
| MyalgiaMusculoskeletal and connective tissue disorders | 75/1177 | 82/1175 | 33/200 | 14/100 | 0/2 |
| Injection site erythemaGeneral disorders | 82/1177 | 86/1175 | 32/200 | 13/100 | 0/2 |
| Injection site swellingGeneral disorders | 79/1177 | 103/1175 | 28/200 | 14/100 | 0/2 |
All vaccinated participants. Includes two participants from Cohort 1 who had unplanned vaccinations with both V116 and PCV20
| Age, Continuous(Years) | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 | Total |
|---|---|---|---|---|---|
| Mean | 63.9 ± 8.3 | 63.9 ± 8.3 | 35.2 ± 9.0 | 34.6 ± 8.7 | 60.7 ± 12.4 |
| Age, Customized(Participants) | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 | Total |
|---|---|---|---|---|---|
| 18 to 49 years | 0 | 0 | 200 | 100 | 300 |
| 50 to 64 years | 589 | 587 | 0 | 0 | 1176 |
| 65 to 74 years | 464 | 464 | 0 | 0 | 928 |
| 75 to 84 years | 112 | 113 | 0 | 0 | 225 |
| ≥85 years | 14 | 13 | 0 | 0 | 27 |
| Sex: Female, Male(Participants) | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 | Total |
|---|---|---|---|---|---|
| Female | 687 | 670 | 137 | 64 | 1558 |
| Male | 492 | 507 | 63 | 36 | 1098 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 259 | 242 | 58 | 24 | 583 |
| Not Hispanic or Latino | 909 | 922 | 141 | 76 | 2048 |
| Unknown or Not Reported | 11 | 13 | 1 | 0 | 25 |
| Race (NIH/OMB)(Participants) | Cohort 1 V116 | Cohort 1 PCV20 | Cohort 2 V116 | Cohort 2 PCV20 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 0 | 1 | 9 |
| Asian | 148 | 168 | 38 | 15 | 369 |
| Native Hawaiian or Other Pacific Islander | 17 | 16 | 1 | 2 | 36 |
| Black or African American | 116 | 115 | 13 | 14 | 258 |
| White | 867 | 844 | 139 | 62 | 1912 |
| More than one race | 26 | 30 | 9 | 6 | 71 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
Showing the first 100 of 112 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2022 to primary completion in May 2023, 10 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 10 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine